LIMN

FULLERTON, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ:LIMN) ("Liminatus" or the "Company"), a biotechnology company developing innovative cancer therapies, today announced that it has engaged Synex Consulting Ltd. ("Synex"), a Korea-based full-service contract research organization ("CRO"), to support the clinical development of IBC101, the Company’s CD19xCD22 bivalent CAR-T cell therapy candidate. The engagement represents an important step in advancing IBC101 toward clinical execution in South Korea. IBC101 has received authorization from the Ministry of Food and Drug Safety of the Republic of Korea (MFDS) for a Phase 1/2a clinical study in patients with re

8-K - Liminatus Pharma, Inc. (0001971387) (Filer)

FULLERTON, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ:LIMN) ("Liminatus" or the "Company") today announced that its board of directors has adopted resolutions approving a reverse stock split of its common stock, par value $0.0001 per share ("Common Stock"), at a ratio of 1-for-50 (the "Reverse Stock Split"), which was approved by stockholders at the Company’s 2026 Annual Meeting of Stockholders held on August 3, 2026. The Reverse Stock Split will take effect at the close of trading on August 20, 2026, and the Company’s Common Stock is expected to begin trading on a split-adjusted basis on The Nasdaq Capital Market under the Company’s existing trading symbol "L

10-Q - Liminatus Pharma, Inc. (0001971387) (Filer)

FULLERTON, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ:LIMN) ("Liminatus" or the "Company"), a biopharmaceutical company developing novel therapies for cancer and other serious diseases, today announced that its common stock was transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective August 4, 2026, and that the Nasdaq Hearings Panel (the "Panel") has granted the Company additional time to demonstrate compliance with Nasdaq’s minimum bid price requirement. The transfer to the Nasdaq Capital Market allows the Company’s common stock to continue trading on Nasdaq under its existing ticker symbol, "LIMN." The Nasdaq Capital Market is one

8-K - Liminatus Pharma, Inc. (0001971387) (Filer)

8-K - Liminatus Pharma, Inc. (0001971387) (Filer)

8-K - Liminatus Pharma, Inc. (0001971387) (Filer)

4 - Liminatus Pharma, Inc. (0001971387) (Issuer)

DEF 14A - Liminatus Pharma, Inc. (0001971387) (Filer)

4 - Liminatus Pharma, Inc. (0001971387) (Issuer)

3 - Liminatus Pharma, Inc. (0001971387) (Issuer)

8-K - Liminatus Pharma, Inc. (0001971387) (Filer)

FULLERTON, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ:LIMN) ("Liminatus" or the "Company"), a biotechnology company developing innovative cancer therapies, today announced that it has amended and restated the previously announced definitive merger agreement with InnocsAI LLC ("InnocsAI"), an oncology biotechnology company focused on next-generation cell therapy technologies. The transaction has been re-structured to allow closing prior to obtaining stockholder approval, with closing now expected to occur on July 2, 2026, subject to the satisfaction or waiver of customary closing conditions. Under the amended terms of the merger agreement, the equity holders

PRE 14A - Liminatus Pharma, Inc. (0001971387) (Filer)

S-1 - Liminatus Pharma, Inc. (0001971387) (Filer)

D - Liminatus Pharma, Inc. (0001971387) (Filer)

8-K - Liminatus Pharma, Inc. (0001971387) (Filer)

424B3 - Liminatus Pharma, Inc. (0001971387) (Filer)

FULLERTON, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ:LIMN) ("Liminatus" or the "Company") today announced that it has entered into a warrant exercise agreement with existing accredited investors to exercise certain outstanding warrants to purchase an aggregate of 10,344,000 shares of common stock of the Company (the "Existing Warrants"). In consideration for the immediate exercise of the Existing Warrants for cash, the exercising holders were issued new unregistered warrants to purchase an aggregate of 20,688,000 million shares of common stock (the "New Warrants"). In connection with the exercise, the Company also agreed to reduce the exercise price of the Ex

8-K - Liminatus Pharma, Inc. (0001971387) (Filer)

FULLERTON, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ:LIMN) ("Liminatus" or the "Company") today announced that the Company received a delisting notice from The Nasdaq Stock Market LLC ("Nasdaq"). As previously disclosed in the Current Report on Form 8-K filed by the Company on November 25, 2025 with the Securities and Exchange Commission (the "SEC"), on November 19, 2025, the Company received notices from Nasdaq indicating that the Company's listed securities failed to comply with the $50,000,000 market value of listed securities (MVLS) requirement for continued listing in accordance with Nasdaq Listing Rule 5450(b)(2)(A) (the "MVLS Rule") and the $15,000,000

FULLERTON, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. ("Liminatus" or the "Company") today announced that it has entered into a definitive Merger Agreement dated May 17, 2026, with InnocsAI LLC ("InnocsAI"), a biotechnology company focused on advanced CAR-T and antibody-based oncology therapies. Under the terms of the Merger Agreement, InnocsAI will merge with and into a newly formed wholly owned Delaware subsidiary of Liminatus, with the subsidiary surviving as a wholly owned subsidiary of the Company. The transaction is intended to expand Liminatus' oncology pipeline with multiple biologic and cellular therapy assets designed to address significant challenges in hem

8-K - Liminatus Pharma, Inc. (0001971387) (Filer)

10-Q - Liminatus Pharma, Inc. (0001971387) (Filer)